A Model Federal Collaborative to Increase Patient Access to Buprenorphine Treatment in HIV Primary Care

Cheever, Laura W.; Kresina, Thomas F.; Cajina, Adan; Lubran, Robert

doi:10.1097/qai.0b013e318209740f

Cited by 30 publications

(30 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[48] Application of these models in behavioral health is a relatively new phenomenon, but it offers great promise in the HIV/AIDS field. [49] This is especially the case in the WIHS cohort given the strong association we observed between continuity of care and standard-concordant depression treatment.…”

Section: Discussionmentioning

confidence: 87%

Do HIV-Positive Women Receive Depression Treatment that Meets Best Practice Guidelines?

et al. 2014

View full text Add to dashboard Cite

This study addressed whether psychopharmacologic and psychotherapeutic treatment of depressed HIV+ women met standards defined in the best practice literature, and tested hypothesized predictors of standard-concordant care. 1,352 HIV-positive women in the multi-center Women’s Interagency HIV Study were queried about depressive symptoms and mental health service utilization using standards published by the American Psychiatric Association and the Agency for Healthcare Quality and Research to define adequate depression treatment. We identified those who: 1) reported clinically significant depressive symptoms (CSDS) using Centers for Epidemiological Studies – Depression Scale (CES-D) scores of ≥ 16; or 2) had lifetime diagnoses of major depressive disorder (MDD) assessed by World Mental Health Composite International Diagnostic Interviews plus concurrent elevated depressive symptoms in the past 12 months. Adequate treatment prevalence was 46.2% (n=84) for MDD and 37.9% (n=211) for CSDS. Multivariable logistic regression analysis found that adequate treatment was more likely among women who saw the same primary care provider consistently, who had poorer role functioning, who paid out-of-pocket for healthcare, and who were not African American or Hispanic/Latina. This suggests that adequate depression treatment may be increased by promoting healthcare provider continuity, outreaching individuals with lower levels of role impairment, and addressing the specific needs and concerns of African American and Hispanic/Latina women.

show abstract

Section: Discussionmentioning

confidence: 87%

Do HIV-Positive Women Receive Depression Treatment that Meets Best Practice Guidelines?

et al. 2014

View full text Add to dashboard Cite

show abstract

“…In 2005, the Miriam Hospital Immunology Center in Providence, RI, was 1 of 10 sites to be awarded a grant by the Health Resources and Services Administration to integrate buprenorphine into an HIV clinic (Cheever et al, 2011). There is a paucity of literature on HCV treatment among coinfected individuals on buprenorphine.…”

mentioning

confidence: 99%

Buprenorphine for Human Immunodeficiency Virus/Hepatitis C Virus–coinfected Patients

Taylor

Maynard

Friedmann

et al. 2012

Journal of Addiction Medicine

View full text Add to dashboard Cite

Objectives Buprenorphine is associated with enhanced human immunodeficiency virus (HIV) treatment outcomes including increased antiretroviral therapy initiation rates, adherence, and CD4+ cell counts among HIV-infected opioid-dependent individuals. Buprenorphine facilitates hepatitis C virus (HCV) treatment in opioid-dependent patients with HCV monoinfection. Less is known about buprenorphine’s role in HIV/HCV coinfection. Methods We conducted a retrospective chart review to evaluate HCV care for HIV-infected buprenorphine patients in the first 4 years of buprenorphine’s integration into a Rhode Island HIV clinic. Results Sixty-one patients initiated buprenorphine. All had HCV antibody testing; 57 (93%) were antibody-positive. All antibody-positive patients underwent HCV RNA testing; 48 (84%) were RNA-positive. Of these, 15 (31%) were not referred to HCV care. Among chronically infected patients, 3 received HCV treatment after buprenorphine; all had cirrhosis and none achieved viral eradication. At buprenorphine induction, most patients had inadequately controlled HIV infection, with detectable HIV RNA (59%) or CD4+ cell count less than or equal to 350/µL (38%). Conclusions Buprenorphine has shown limited success to date as a bridge to HCV treatment within an HIV clinic. Buprenorphine’s stabilization of opioid dependence and HIV disease may permit the use of HCV therapy over time.

show abstract

“…As described more fully in this supplement, [13][14][15] from 2004 to 2009, the HIV/AIDS Bureau of the Health Resources and Services Administration funded, through its Special Projects of National Significance (SPNS), the development of demonstration programs that integrated HIV care and bup/nx treatment for opioid dependence at 10 sites across the United States. Health Resources and Services Administration also funded an Evaluation and Technical Assistance Center (the Center) to coordinate the multisite evaluation, provide clinical and evaluation support and technical assistance, and promote dissemination of findings.…”

Section: Methodsmentioning

confidence: 99%

Hepatic Safety and Lack of Antiretroviral Interactions With Buprenorphine/Naloxone in HIV-Infected Opioid-Dependent Patients

Vergara-Rodriguez¹,

Tozzi²,

Botsko³

et al. 2011

JAIDS Journal of Acquired Immune Deficiency Syndromes

View full text Add to dashboard Cite

show abstract

A Model Federal Collaborative to Increase Patient Access to Buprenorphine Treatment in HIV Primary Care

Cited by 30 publications

References 16 publications

Do HIV-Positive Women Receive Depression Treatment that Meets Best Practice Guidelines?

Do HIV-Positive Women Receive Depression Treatment that Meets Best Practice Guidelines?

Buprenorphine for Human Immunodeficiency Virus/Hepatitis C Virus–coinfected Patients

Hepatic Safety and Lack of Antiretroviral Interactions With Buprenorphine/Naloxone in HIV-Infected Opioid-Dependent Patients

Contact Info

Product

Resources

About